Redefining
obesity treatment,
empowering patients
At Antag Therapeutics, we are pioneering a new class of therapies for people living with obesity, diabetes and overweight. Our mission is to provide personal treatment options that go beyond weight loss to achieve long-term sustained health, without having to compromise on tolerability.
Obesity is a complex, chronic condition affecting millions of people worldwide, and it is closely linked to type 2 diabetes, cardiovascular disease, and a range of metabolic disorders. While substantial progress has been made, many current therapies have significant drawbacks, including gastrointestinal side effects and loss of lean mass. Moreover, despite advances in obesity management, a large proportion of people still do not achieve their intended weight-loss goals with existing treatment options. Hence more innovation and new mechanisms of action are required to address these shortcomings.
At Antag, we are focused on redefining obesity treatment to better reflect the biological complexity of the disease and cater to the individual needs of every patient.
A differentiated
approach to obesity
treatment
Antag is pioneering a new kind of obesity treatment: GIP receptor antagonism. Unlike therapies that stimulate incretin hormones to suppress appetite, this approach blocks a dysfunctional biological pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction.
Our lead candidate, AT-7687, is the first clinical-stage GIP receptor antagonist peptide, designed to target and deactivate the GIP receptor. AT-7687 is being investigated both as a monotherapy and in combination with other obesity therapies, with a view to providing effective weight loss and long-term health benefits without compromising on tolerability.
Antag’s truly novel approach is designed to enable adaptable care and healthier, sustained outcomes for people living with obesity.
Delivering long-term sustained health,
without compromising
on tolerability
A differentiated approach to obesity treatment
Antag is pioneering a new kind of obesity treatment: GIP receptor antagonism. Unlike therapies that stimulate incretin hormones to suppress appetite, this approach blocks a dysfunctional biological pathway that contributes to fat storage, insulin resistance, and metabolic dysfunction.
Our lead candidate, AT-7687, is the first clinical-stage GIP receptor antagonist peptide, designed to target and deactivate the GIP receptor. AT-7687 is being investigated both as a monotherapy and in combination with other obesity therapies, with a view to providing effective weight loss and long-term health benefits without compromising on tolerability.
Antag’s truly novel approach is designed to enable adaptable care and healthier, sustained outcomes for people living with obesity.
Delivering long-term sustained health,
without compromising on tolerability
A team of world-class experts
Antag Therapeutics was founded by experts in obesity and incretin biology, including Professor Jens Juul Holst, discoverer of GLP-1 and a pioneer in incretin biology, with its GIPR antagonist approach stemming from the work of the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde.
Our leadership team combines deep scientific expertise with decades of drug development experience, positioning us to shape the future of obesity care.
Latest News
Antag Therapeutics expands senior team to support clinical progress
Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the Company’s next phase of growth following the recent initiation of a Phase 1 trial of...
Antag Therapeutics initiates Phase 1a trial of AT-7687, a first-in-class GIPR antagonist designed to address key gaps in obesity treatment
First subjects dosed in double-blind, placebo-controlled trial assessing AT-7687’s safety, tolerability, pharmacokinetics, and metabolic effects in healthy lean subjects and subjects living with obesity With strong genetic and...
Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company prepares to start clinical development of its first in-class lead candidate, AT-7687 in obesity AT-7687 offers a...
Let's connect
Ready to learn more or connect with our team?